Expert Analysis - Opinion

Gilead Ruling Signals That Innovating Can Lead To Liability

By Gary Myers · February 6, 2024, 5:15 PM EST

The Court of Appeal of the State of California ruled last month that a drug manufacturer can be liable for negligence for its delay in introducing an improved version of its...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Related Sections

Featured Stories

Justices To Clarify What's Fair Game With 'Skinny Labels' No Photo Available

Ryan Davis

A new U.S. Supreme Court patent case that will require the justices to spell out what generic-drug makers can say when marketing drugs... (more story)

What JPM Tells Us About Healthcare Deals In 2026 No Photo Available

Yeji Jesse Lee

Coming out of one of the bellwether events for the healthcare industry, attorneys in the space are feeling pretty good about 2026.

Biopharma Industry Cheers US, EU's Joint AI Principles No Photo Available

Dan McKay

A cross-Atlantic effort by regulators shows that U.S. and European agencies can find common ground to guide the life sciences industry... (more story)